Abstract
Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) is an immunoregulatory molecule expressed by activated T cells and resting CD4+CD25 + T cells. In patients with advanced melanoma, our group reported that administration of anti-CTLA-4 antibody mediated objective cancer regression in 13% of patients. This study also established that the blockade of CTLA-4 was associated with grade III/IV autoimmune manifestations that included dermatitis, enterocolitis, hepatitis, uveitis, and a single case of hypophysitis. Since this initial report, 7 additional patients with anti-CTLA-4 antibody-induced autoimmune hypophysitis have been accumulated. The characteristics, clinical course, laboratory values, radiographic findings, and treatment of these 8 patients are the focus of this report.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 593-598 |
| Number of pages | 6 |
| Journal | Journal of Immunotherapy |
| Volume | 28 |
| Issue number | 6 |
| State | Published - Nov 2005 |
| Externally published | Yes |
Fingerprint
Keywords
- Anti-CTLA-4 antibody
- Autoimmune hypophysitis
- Autoimmunity
- Immunotherapy
- Melanoma
- Renal cell cancer
ASJC Scopus subject areas
- Cancer Research
- Pharmacology
- Immunology
Cite this
Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. / Blansfield, Joseph A.; Beck, Kimberly E.; Tran, Khoi; Yang, James C.; Hughes, Marybeth S.; Kammula, Udai S.; Royal, Richard E.; Topalian, Suzanne; Haworth, Leah R.; Levy, Catherine; Rosenberg, Steven A.; Sherry, Richard M.
In: Journal of Immunotherapy, Vol. 28, No. 6, 11.2005, p. 593-598.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer
AU - Blansfield, Joseph A.
AU - Beck, Kimberly E.
AU - Tran, Khoi
AU - Yang, James C.
AU - Hughes, Marybeth S.
AU - Kammula, Udai S.
AU - Royal, Richard E.
AU - Topalian, Suzanne
AU - Haworth, Leah R.
AU - Levy, Catherine
AU - Rosenberg, Steven A.
AU - Sherry, Richard M.
PY - 2005/11
Y1 - 2005/11
N2 - Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) is an immunoregulatory molecule expressed by activated T cells and resting CD4+CD25 + T cells. In patients with advanced melanoma, our group reported that administration of anti-CTLA-4 antibody mediated objective cancer regression in 13% of patients. This study also established that the blockade of CTLA-4 was associated with grade III/IV autoimmune manifestations that included dermatitis, enterocolitis, hepatitis, uveitis, and a single case of hypophysitis. Since this initial report, 7 additional patients with anti-CTLA-4 antibody-induced autoimmune hypophysitis have been accumulated. The characteristics, clinical course, laboratory values, radiographic findings, and treatment of these 8 patients are the focus of this report.
AB - Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) is an immunoregulatory molecule expressed by activated T cells and resting CD4+CD25 + T cells. In patients with advanced melanoma, our group reported that administration of anti-CTLA-4 antibody mediated objective cancer regression in 13% of patients. This study also established that the blockade of CTLA-4 was associated with grade III/IV autoimmune manifestations that included dermatitis, enterocolitis, hepatitis, uveitis, and a single case of hypophysitis. Since this initial report, 7 additional patients with anti-CTLA-4 antibody-induced autoimmune hypophysitis have been accumulated. The characteristics, clinical course, laboratory values, radiographic findings, and treatment of these 8 patients are the focus of this report.
KW - Anti-CTLA-4 antibody
KW - Autoimmune hypophysitis
KW - Autoimmunity
KW - Immunotherapy
KW - Melanoma
KW - Renal cell cancer
UR - http://www.scopus.com/inward/record.url?scp=27444440093&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=27444440093&partnerID=8YFLogxK
M3 - Article
C2 - 16224277
AN - SCOPUS:27444440093
VL - 28
SP - 593
EP - 598
JO - Journal of Immunotherapy
JF - Journal of Immunotherapy
SN - 1524-9557
IS - 6
ER -